Dinoprostone

Indications
 Extra-amniotic
Pregnancy termination in the 2nd trimester
Adult: As 100 mcg/mL soln: Instill 1 mL through a suitable foley catheter followed by 1-2 mL at 2-hr intervals according to patient's response.
Vaginal
Cervical priming, induction and augmentation of labour
Adult: As cervical gel: Apply 500 mcg in 2.5 mL preparation. May be repeated after 6 hr if necessary. Max: 1.5 mg/24 hr.
Vaginal
Labour induction
Adult: As vaginal gel: 1 mg (or 2 mg for primigravid patients with unfavourable induction features) followed by another 1 or 2 mg after 6 hr if necessary. Max: 3 mg (or 4 mg in unfavourable primigravid patients). As pessary: Initially, 3 mg followed by a further 3 mg after 6-8 hr if necessary. Max: 6 mg.
Contraindications
 Hypersensitivity to prostaglandins. Patients in whom oxytocics are generally contraindicated. History of pelvic inflammatory disease; active cardiac, pulmonary, renal or hepatic disease.
Warnings / Precautions
 Raised intraocular pressure. Previous caesarean section; history of asthma, epilepsy, hepatic or renal dysfunction, cardiovascular disease; pregnancy.
Adverse Reactions
 Hypersensitivity reactions, nausea, vomiting, diarrhoea, abdominal pain; flushing, shivering, headache, dizziness; hypertension; convulsions, ECG changes,local tissue irritation, erythema; pyrexia, increased WBC. Uterine contractile abnormalities with or without foetal distress. Dosage >0.5 mg intracervically can cause hypertonic uterine contractions. Intra/extra-amniotic inj: Local infection, vomiting, diarrhoea, pyrexia, transient hypotension.
Potentially Fatal: Sudden CV collapse due to accidental IV absorption and intra-amniotic inj. Uterine rupture, amniotic fluid embolism during labour. Foetal distress and death in rare cases.
Overdose Reactions
 Rigors, vomiting, severe abdominal pain, uterine hypercontractility and uterine hypertonus. Management: conservative management may be sufficient in most cases. β-adrenergic drugs may be used as a treatment of hyperstimulation following admin for cervical ripening.
Drug Interactions
 Potentially Fatal: Concomitant use of oxytocin may lead to uterine rupture.
See Below for More dinoprostone Drug Interactions
Mechanism of Actions
 Dinoprostone causes induction of uterine muscle contraction during pregnancy. It is both a vasoconstrictor and bronchodilator. The pattern of uterine contraction is similar to that in normal labour at term. It can also stimulate the smooth muscle of the GI tract.
Onset: 10 min.
Duration: 2-3 hr (vaginal supp).
Absorption: Small amounts absorbed by the uterus.
Distribution: Diffuses into the maternal blood.
Metabolism: Hepatic, renal, spleen and other tissues: Rapid.
Excretion: Urine; faeces (small amounts).
Storage Conditions
 Extra-amniotic: Cervical gel: Refrigerate at 2-8°C. Vag supp: Store in a freezer below -20°C. Vag insert: Store in a freezer between -20°C & -10°C. Vaginal: Cervical gel: Refrigerate at 2-8°C. Vag supp: Store in a freezer below -20°C. Vag insert: Store in a freezer between -20°C & -10°C.
ATC Classification
 G02AD02 - dinoprostone ; Belongs to the class of prostaglandins. Used to induce abortion or augment labour and to minimize blood loss from the placental site.
Storage
 Extra-amniotic: Cervical gel: Refrigerate at 2-8°C. Vag supp: Store in a freezer below -20°C. Vag insert: Store in a freezer between -20°C & -10°C. Vaginal: Cervical gel: Refrigerate at 2-8°C. Vag supp: Store in a freezer below -20°C. Vag insert: Store in a freezer between -20°C & -10°C.
Available As
  • Dinoprostone 0.5 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Dinoprostone


    Dinoprostone Containing Brands

    We are Developing Our database, More results coming soon.

    Dinoprostone is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Dinoprostone

    We are Developing Our database, More results coming soon.